Crucell N.V. Announces STAR(R) Technology Research License with Korean-based ISU ABXIS CO., LTD
Published: Jan 14, 2008
LEIDEN, NETHERLANDS--(Marketwire - January 14, 2008) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STAR® research license agreement with Korean-based ISU ABXIS. The license covers both a research evaluation of STAR® technology for the production of recombinant proteins and an option for a commercial license. Financial details of the agreement were not disclosed.